(Press-News.org) April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks (71%, p END
Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
Results from the ground-breaking new BOSON study
2015-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infection
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.
The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...
Sofosbuvir/daclatasvir combination effective treatment for difficult-to-treat hep C patients
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.
Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...
DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
2015-04-25
April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 ...
Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
2015-04-25
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients
2015-04-25
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing
2015-04-25
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
Use of pocket-sized ultrasound device reduces need for further testing in clinical settings
2015-04-25
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
2015-04-25
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...
Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment
2015-04-25
Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.
Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...
Mental disorders don't predict future violence
2015-04-25
Depression is not linked to violence among males
Some delinquent youth with current psychiatric illness may be violent
Providing treatment could reduce violence
CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence.
"Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...
LAST 30 PRESS RELEASES:
USC team demonstrates first optical device based on “optical thermodynamics”
Microplastics found to change gut microbiome in first human-sample study
Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds
Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields
Yeast proteins reveal the secrets of drought resistance
Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition
New Canadian study reveals where HIV hides in different parts of the body
Lidocaine poisonings rise despite overall drop in local anesthetic toxicity
Politics follow you on the road
Scientists blaze new path to fighting viral diseases
The mouse eye as a window to spotting systemic disease
AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs
FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials
Exploring the therapeutic potential of cannabidiol for Alzheimer's
We need a solar sail probe to detect space tornadoes earlier, more accurately, U-M researchers say
Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results
Sperm microRNAs: Key regulators of the paternal transmission of exercise capacity
Seeing double: Clever images open doors for brain research
Inhaler-related greenhouse gas emissions in the US
UCLA Health study finds inhalers for asthma and COPD drive significant greenhouse gas emissions
A surgical handover system for patient physiology and safety
Cardiovascular health changes in young adults and risk of later-life cardiovascular disease
Nurse workload and missed nursing care in neonatal intensive care units
How to solve the remote work stalemate – dissertation offers tools for successful hybrid work
Chip-based phonon splitter brings hybrid quantum networks closer to reality
Texas Children’s researchers create groundbreaking tool to improve accuracy of genetic testing
Milken Institute, Ann Theodore Foundation announce more than $2.5 million in new funding for sarcoidosis research and launch new call for proposals
Boston University professor to receive 2025 Eugene Braunwald Academic Mentorship Award
Pusan National University researchers reveal how forest soil properties influence arsenic mobility and toxicity in soil organisms
Korea University researchers find sweet taste cells resist nerve damage through c-Kit protein
[Press-News.org] Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patientsResults from the ground-breaking new BOSON study